Trials / Completed
CompletedNCT01690507
Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）
Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML）
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 55 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Demethylating agent decitabine enhances the immunogenicity of leukemia cells by inducing the expression of cancer testis antigens (CTAs),MHC class I and II molecules,costimulatory molecules and adhesion molecules. The leukemias cells treated by decitabine will become more sensitive to the following adoptive T cell therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Decitabine | 20 mg/m²/day for 5 days |
| DRUG | Cytarabine | |
| DRUG | aclacinomycin | |
| DRUG | Granulocyte colony-stimulating factor | |
| OTHER | HLA haploidentical mononuclear cells infusion |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2015-05-01
- Completion
- 2016-01-01
- First posted
- 2012-09-21
- Last updated
- 2016-02-25
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01690507. Inclusion in this directory is not an endorsement.